Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, announced yesterday it has named Jared Gollob, MD as its new chief medical officer.

Dr Gollob was vice president of Clinical Development and global vice president of Medical Affairs at Alnylam Pharmaceuticals. Prior to joining Alnylam, Dr Gollob held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. Dr Gollob has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals.

Laurent Audoly, PhD, CEO, Kymera Therapeutics, said, 'Kymera is a company of great people built on great science. We are rapidly advancing our first drug candidate toward the clinic, and thrilled to welcome Jared to the Kymera team to support our move to become a fully integrated biotech company. Jared brings invaluable experience in drug development and leveraging novel discovery platforms to successfully launch new therapies for patients. He also has incredible depth of knowledge in translational immunology and tumour biology – key areas of focus for the company.'